ANI Pharmaceuticals IncANIP
▲ PositiveCapitalrelevance
Q2 revenue and EPS beat estimates, and guidance reaffirmed.
Impact on stocks 1
Aging Population
ANI Pharmaceuticals IncANI Pharmaceuticals Q2 Earnings Call: Top 5 Analyst Questions
Earnings
ANI Pharmaceuticals reported second-quarter revenue of $266 million, beating analyst estimates of $259.8 million and growing 25.9% year over year, while adjusted EPS of $2.21 also topped expectations of $2.04. The company reconfirmed full-year revenue guidance of $1.11 billion at the midpoint and reiterated adjusted EPS guidance of $9.44 at the midpoint. During the earnings call, analysts focused on the ramp of Cortrophin Gel, with CEO Nikhil Lalwani noting that July represented the highest month for new cases initiated and that insurance reverification issues were no longer a factor in Q2. Management attributed a lowered Cortrophin guidance to first-half performance rather than deteriorating trends, and highlighted strong leading indicators from the expanded sales force. The company's market capitalization stands at $1.60 billion, with shares trading at $74.77 after the earnings release.
ANI Pharmaceuticals IncQ2 revenue and EPS beat estimates, and guidance reaffirmed.